

Transcranial Photobiomodulation Attenuates PTSD-Like Fear Memory and Remodels Hippocampal Monoaminergic Signaling in Rats

Peibin Zou^{1,2}, Zhihai Huang^{1,2}, Yulan Zhang¹, Jiahao Zhang¹, Yidan Liang¹, Junhui Wang¹, Chao Tang¹, Ning Yang¹, Qinqin Xu¹, J. Dedrick Jordan³, Quanguang Zhang^{1,2}, Xuemei Zong^{1,2}

¹Department of Neurology, ²Department of Pharmacology, Toxicology, and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, USA.

³Department of Neurology, College of Medicine – Tucson, The University Of Arizona, Tucson, AZ, USA.



Introduction

Introduction: Post-traumatic stress disorder (PTSD) involves persistent maladaptive fear memory and limited treatment efficacy. Photobiomodulation (PBM) is a noninvasive neuromodulatory approach with translational potential, but its effects in PTSD remain unclear. This study tested whether transcranial PBM reduces PTSD-like fear in rats and whether effects are linked to hippocampal bioenergetics and monoaminergic signaling.

Methods: Rats underwent tone-shock conditioning and restraint stress. PBM (810 nm, 2 min) was applied post-stress. Fear memory was assessed at early and remote time points. Hippocampal ATP, norepinephrine (NE), corticosterone (CORT), and serum markers were measured. RNA-seq was performed 5 h after PBM.

Results: PBM did not affect early contextual fear but reduced cued freezing at 24 h. PBM increased hippocampal ATP and monoamines (NE), with limited CORT changes. Transcriptomics revealed alterations in monoamine-related genes (Tph1, Htr2c, Rab38, Myo5a).

Conclusions: Transcranial PBM attenuates persistent PTSD-like fear, potentially via enhanced bioenergetics and monoaminergic modulation, supporting its promise as a scalable, noninvasive intervention for trauma-related disorders.

Results




Fig.1. Experimental design and PBM parameters. **A)** Timeline of tone-shock fear conditioning, restraint stress, PBM treatment, contextual memory test, and cued memory test. **B)** PBM was delivered at 810 nm for 2 min under continuous-wave mode, with tested irradiance at the scalp, skull, and cortex.

PBM Wavelength	810nm
Power	80 mW/cm ² , scalp 52 mW/cm ² , skull 40 mW/cm ² , cortex
Irradiation time	2 min
Beam area	1.5 cm ²
Pulse parameters	continuous wave




Fig. 2. PBM reduces cued fear memory. **A–B)** PBM did not change freezing during fear conditioning or contextual memory testing. **C)** PBM significantly reduced cued freezing on Day 3. Data are shown as mean ± SEM.






Fig. 3. PBM increases hippocampal ATP and norepinephrine. **A)** Timeline for biochemical sample collection after restraint stress and PBM treatment. **B)** PBM increased hippocampal ATP levels after stress. **C–D)** PBM increased serum and hippocampal norepinephrine levels. **E)** Serum corticosterone levels were measured across post-stress time points. N=4 each point, Data are shown as mean ± SEM.




Fig. 4. PBM alters hippocampal monoamine-related gene expression. **A)** Timeline for hippocampal bulk RNA-seq collection. **B–C)** Heatmaps of genes enriched in phenol-containing compound metabolic and biosynthetic processes (two of the Top 10 changed GO pathways) across Control, Res, and PBM groups.

Conclusion

- Transcranial PBM attenuated PTSD-like cued fear memory.
- PBM enhanced hippocampal ATP and norepinephrine levels.
- PBM altered hippocampal monoamine-related transcriptional profiles.

Acknowledgements

RF1NS135548, R01AG082207, R01AG083947, R01AG081874, 24CDA1269588, Department of Defense under Award Number HT9425-24-1-0663, Institute for Cerebrovascular & Neurodegeneration Research, Department of Pharmacology, Toxicology, and Neuroscience, LSU Research Council